Publisher Modification: Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a period 1 test

medicine

.Nature Medicine, Published online: 16 October 2024 doi:10.1038/ s41591-024-03348-1Publisher Improvement: Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a period 1 trial.